about
Technologies for controlled, local delivery of siRNACyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics.Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary FibrosisGold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery.Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery.In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.Early endosomal escape of a cyclic cell-penetrating peptide allows effective cytosolic cargo delivery.Cationic amphiphilic macromolecule (CAM)-lipid complexes for efficient siRNA gene silencing.Dynamics of nucleic acid/cationic polymer complexation and disassembly under biologically simulated conditions using in situ atomic force microscopy.Efficient and targeted delivery of siRNA in vivo.Lipid and polymeric carrier-mediated nucleic acid delivery.Spherical nucleic acids as a divergent platform for synthesizing RNA-nanoparticle conjugates through enzymatic ligation.Delivery of siRNA therapeutics: barriers and carriers.Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugationOptimized method for the synthesis and purification of adenosine--folic acid conjugates for use as transcription initiators in the preparation of modified RNA.Degradable polyelectrolyte multilayers that promote the release of siRNAMonitoring penetratin interactions with lipid membranes and cell internalization using a new hydration-sensitive fluorescent probe.Light-mediated activation of siRNA Release in diblock copolymer assemblies for controlled gene silencing.Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group.Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer Therapy.Reductively responsive siRNA-conjugated hydrogel nanoparticles for gene silencing.Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells.In vivo inhibition of influenza A virus replication by RNA interference targeting the PB2 subunit via intratracheal delivery.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery SystemsRNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applicationsAdvanced materials and processing for drug delivery: the past and the future.Circularized synthetic oligodeoxynucleotides serve as promoterless RNA polymerase III templates for small RNA generation in human cells.Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromoleculesDocosahexaenoic Acid Conjugation Enhances Distribution and Safety of siRNA upon Local Administration in Mouse BrainFLEth RNA intercalating probe is a convenient reporter for small interfering RNAsTherapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system.Peptide-functionalized nanogels for targeted siRNA delivery.Strategies for targeted nonviral delivery of siRNAs in vivo.Site-specific antibody-polymer conjugates for siRNA delivery.Clinical developments in nanotechnology for cancer therapy.Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles.Engineering Nanocarriers for siRNA Delivery.Self-assembled and nanostructured siRNA delivery systems.Nanocarriers: a tool to overcome biological barriers in siRNA delivery.Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review.
P2860
Q28087657-21C82E6A-4497-4FD9-AE93-E915A09212C7Q30574647-8283E485-9C32-4462-8EB4-D03D83B9BBA4Q30734485-D0E478B9-972D-4639-966D-6A18EA3A8B59Q33440795-B5A237C4-A2D9-4146-A3DA-72752A1F9C2FQ33660805-43732A4D-9FD0-4CEE-9BD0-8ED72FDC9394Q33765102-6E18C65E-B311-4C32-91ED-4910FCCDF57BQ33824686-517B2D72-9EB6-40A2-B109-91D71C38EA98Q33875414-9D035D80-267B-45CB-BB49-D5F1A8548CB5Q34097275-30682B6D-04AA-4487-94BD-D717E8ACAF78Q34149828-3D604476-CBF0-47C4-87C7-D9C97A88D9C6Q34155795-00AC1E08-D1DB-42E6-87BA-964B083BB551Q34239177-96EB2BB3-9065-40DC-9A29-BD7847E10E00Q34293708-45014701-A13D-4519-A1D5-FB6991EFA0CBQ34389283-0121BDC9-723A-4BE8-9165-EDC7FA615E89Q34961061-63004CC3-0895-42E3-8FC0-2CB161B727D0Q35046391-BF835C72-6B38-4DC3-BEF6-D87DFBC81086Q35215082-7F087145-4DB1-43A8-AD1F-0E5DC7548B14Q35598648-62A93C21-92BB-40AC-9E23-E91B1180CCBCQ35823611-6B3EEEA0-6807-40C2-B2FC-C7C282C57219Q35831738-25E87BE4-23EB-4191-AC6F-9B76ECAB1D5BQ35975665-9E164AD0-7827-4BFD-AACA-291A70FAF1C8Q36170747-A206FA3D-34A8-4383-944C-83F15F57C788Q36335944-E4E394C1-56F2-4A0B-A99A-E9629C4B2867Q36341433-BFF5B40E-3E1A-4C6C-B82B-3AB86D7E9FD9Q36449335-36E11C36-E80C-42C7-B8FD-9F9B448A5C85Q36589333-2923EC10-5D20-4599-9E43-66960844C401Q36619965-23A6BBE1-8976-40BE-BDE1-802048D089EAQ37194010-363805FF-9181-4051-B77F-881CF9BF9A0FQ37256184-80A93E81-395B-480F-B007-3F196A253832Q37316951-5A3ACC3E-62A8-4D0C-B887-4DB1C449A18CQ37330601-94016042-DBFD-4B74-9DF2-D2EEDA623D80Q37395691-5BF723E4-C5F6-48F3-9DCC-B211AB10EEE6Q37619111-6588BAE4-900B-4C82-9330-6A014A1B860EQ37638814-3C699152-1E99-4B11-BC04-279F965D6D7FQ37765187-65219BBC-739D-4A01-B5CE-071E4DBF6F59Q37793079-C93657D6-A2F0-43FA-B1EE-BBFBD8EA624EQ37849727-4015B00C-9B1A-4EB1-8121-CF2C6D2B0E65Q37855596-BA631F14-C393-4335-902F-6BE2B9B12BB9Q37891091-FD16736C-8638-4487-B399-7755991B00FAQ37922198-D45CC74B-A988-4DB4-B452-63C286474C2D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
siRNA conjugate delivery systems.
@en
siRNA conjugate delivery systems.
@nl
type
label
siRNA conjugate delivery systems.
@en
siRNA conjugate delivery systems.
@nl
prefLabel
siRNA conjugate delivery systems.
@en
siRNA conjugate delivery systems.
@nl
P2093
P356
P1476
siRNA conjugate delivery systems.
@en
P2093
Hyejung Mok
Ji Hoon Jeong
Tae Gwan Park
Yu-Kyoung Oh
P356
10.1021/BC800278E
P577
2009-01-01T00:00:00Z